Hemophilia Gene Therapy - A Pipeline Analysis Report

Hemophilia Gene Therapy - A Pipeline Analysis Report

  • October 2017 •
  • 105 pages •
  • Report ID: 5166339 •
  • Format: PDF
Hemophilia Gene Therapy: An insight

Hemophilia is an inherited bleeding disorder. The gene responsible for hemophilia is present on the X chromosome and is inherited in a recessive manner. Hemophilia A, also called as factor VIII (FVIII) deficiency or classic hemophilia, is caused by missing or defective factor VIII. Most individuals, roughly 85%, have hemophilia A and produce too little or no factor VIII. On the other hand, hemophilia B, which is also called Christmas disease, is caused by a deficiency of factor IX.

Shire became the biggest hemophilia player after it bought Baxalta in June 2016, and the company reported total hemophilia revenue of $870.9 million in the FY2016.

Covered in this report
The report covers the present scenario and the growth prospects of the hemophilia gene therapy. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio’s Hemophilia Gene Therapy - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.

Major companies
• uniQure
• Alnylam Pharmaceuticals
• BioMarin Pharmaceutical
• Spark Therapeutics
• Shire

Key questions answered in this report
• How will the market evolve during the forecast period?
• What are the major parameters impacting the market?
• What are the key market trends?
• What are the challenges to market growth?
• Who are the key companies in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.